Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old
Abstract Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 ≥65-year-old subjects in a randomized clinical trial. Virol...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2009-12, Vol.28 (2), p.379-385 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 385 |
|---|---|
| container_issue | 2 |
| container_start_page | 379 |
| container_title | Vaccine |
| container_volume | 28 |
| creator | Keitel, W.A Treanor, J.J El Sahly, H.M Gilbert, A Meyer, A.L Patriarca, P.A Cox, M.M |
| description | Abstract Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 ≥65-year-old subjects in a randomized clinical trial. Virologic surveillance for influenza-like illness (ILI) was conducted during the 2006–2007 epidemic. Vaccines were well tolerated. Seroconversion rates vs. influenza A/H1N1 and H3N2 antigens were superior in the rHA group, but were inferior vs. influenza B; however, results for influenza B are confounded since the vaccine antigens were different. ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted. |
| doi_str_mv | 10.1016/j.vaccine.2009.10.037 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733603122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X09015679</els_id><sourcerecordid>21166139</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-9ff764c264f52ff8ff3ef608832cc719d64dfdc486ee697fa2120cbbb808d6f93</originalsourceid><addsrcrecordid>eNqFks-KFDEQxhtR3HH1EZSAoOuhx_zpTicXZRnUXVjw4CreQiZdGTN2J2PSPTC-gQcfwxfzSUw7DQt70FOg-NVX-eqronhM8JJgwl9ul3ttjPOwpBjLXFti1twpFkQ0rKQ1EXeLBaa8KiuCP58UD1LaYoxrRuT94oRI0UhK6aL4uQr9Tkc9uD0g1_ejDxvwzrjhgIJFEUzo185rPyDnbTeC_67RF-j1ZtONg_POo7N4cf4Cad-iIbq97uAvq02W1AO0aP4nOru-_JS5PvgN2kFMwSf0-8cvXqMD6JhQ6NqHxT2ruwSP5ve0-Pj2zfXqorx6_-5ydX5VmqoRQymtbXhlsjtbU2uFtQwsx0IwakxDZMur1ramEhyAy8ZqSig26_VaYNFyK9lp8fyou4vh2whpUL1LBrpOewhjUg1jHDNCaSaf_ZOkhHBO2CT59Ba4DWP02YUinAhJG1mRTNVHysSQUgSrdtH1Oh4UwWrKVW3VvC815TqVc66578msPq57aG-65iAz8PoIQF7b3kFUyTjwBlqXMxxUG9x_R7y6pWC6nK_R3Vc4QLpxoxJVWH2Yjmu6LSwxqXkj2R8xi84V</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1618927941</pqid></control><display><type>article</type><title>Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Keitel, W.A ; Treanor, J.J ; El Sahly, H.M ; Gilbert, A ; Meyer, A.L ; Patriarca, P.A ; Cox, M.M</creator><creatorcontrib>Keitel, W.A ; Treanor, J.J ; El Sahly, H.M ; Gilbert, A ; Meyer, A.L ; Patriarca, P.A ; Cox, M.M</creatorcontrib><description>Abstract Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 ≥65-year-old subjects in a randomized clinical trial. Virologic surveillance for influenza-like illness (ILI) was conducted during the 2006–2007 epidemic. Vaccines were well tolerated. Seroconversion rates vs. influenza A/H1N1 and H3N2 antigens were superior in the rHA group, but were inferior vs. influenza B; however, results for influenza B are confounded since the vaccine antigens were different. ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2009.10.037</identifier><identifier>PMID: 19879222</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Aged ; Allergy and Immunology ; Antigens ; Comparative immunogenicity ; Eggs ; Hemagglutinin Glycoproteins, Influenza Virus - immunology ; Humans ; Illnesses ; Immune responses ; Immunization ; Immunogenicity ; Influenza vaccines ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - adverse effects ; Influenza Vaccines - immunology ; Licenses ; Multicenter Studies as Topic ; Older people ; Proteins ; Recombinant hemagglutinin ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - adverse effects ; Recombinant Proteins - immunology ; Seasons ; Studies ; Surveillance ; Swine flu ; Vaccines ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - adverse effects ; Vaccines, Inactivated - immunology ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - adverse effects ; Vaccines, Synthetic - immunology</subject><ispartof>Vaccine, 2009-12, Vol.28 (2), p.379-385</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Dec 11, 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-9ff764c264f52ff8ff3ef608832cc719d64dfdc486ee697fa2120cbbb808d6f93</citedby><cites>FETCH-LOGICAL-c478t-9ff764c264f52ff8ff3ef608832cc719d64dfdc486ee697fa2120cbbb808d6f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1618927941?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19879222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keitel, W.A</creatorcontrib><creatorcontrib>Treanor, J.J</creatorcontrib><creatorcontrib>El Sahly, H.M</creatorcontrib><creatorcontrib>Gilbert, A</creatorcontrib><creatorcontrib>Meyer, A.L</creatorcontrib><creatorcontrib>Patriarca, P.A</creatorcontrib><creatorcontrib>Cox, M.M</creatorcontrib><title>Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 ≥65-year-old subjects in a randomized clinical trial. Virologic surveillance for influenza-like illness (ILI) was conducted during the 2006–2007 epidemic. Vaccines were well tolerated. Seroconversion rates vs. influenza A/H1N1 and H3N2 antigens were superior in the rHA group, but were inferior vs. influenza B; however, results for influenza B are confounded since the vaccine antigens were different. ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted.</description><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Antigens</subject><subject>Comparative immunogenicity</subject><subject>Eggs</subject><subject>Hemagglutinin Glycoproteins, Influenza Virus - immunology</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immune responses</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Influenza vaccines</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - adverse effects</subject><subject>Influenza Vaccines - immunology</subject><subject>Licenses</subject><subject>Multicenter Studies as Topic</subject><subject>Older people</subject><subject>Proteins</subject><subject>Recombinant hemagglutinin</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Recombinant Proteins - immunology</subject><subject>Seasons</subject><subject>Studies</subject><subject>Surveillance</subject><subject>Swine flu</subject><subject>Vaccines</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - adverse effects</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - adverse effects</subject><subject>Vaccines, Synthetic - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks-KFDEQxhtR3HH1EZSAoOuhx_zpTicXZRnUXVjw4CreQiZdGTN2J2PSPTC-gQcfwxfzSUw7DQt70FOg-NVX-eqronhM8JJgwl9ul3ttjPOwpBjLXFti1twpFkQ0rKQ1EXeLBaa8KiuCP58UD1LaYoxrRuT94oRI0UhK6aL4uQr9Tkc9uD0g1_ejDxvwzrjhgIJFEUzo185rPyDnbTeC_67RF-j1ZtONg_POo7N4cf4Cad-iIbq97uAvq02W1AO0aP4nOru-_JS5PvgN2kFMwSf0-8cvXqMD6JhQ6NqHxT2ruwSP5ve0-Pj2zfXqorx6_-5ydX5VmqoRQymtbXhlsjtbU2uFtQwsx0IwakxDZMur1ramEhyAy8ZqSig26_VaYNFyK9lp8fyou4vh2whpUL1LBrpOewhjUg1jHDNCaSaf_ZOkhHBO2CT59Ba4DWP02YUinAhJG1mRTNVHysSQUgSrdtH1Oh4UwWrKVW3VvC815TqVc66578msPq57aG-65iAz8PoIQF7b3kFUyTjwBlqXMxxUG9x_R7y6pWC6nK_R3Vc4QLpxoxJVWH2Yjmu6LSwxqXkj2R8xi84V</recordid><startdate>20091211</startdate><enddate>20091211</enddate><creator>Keitel, W.A</creator><creator>Treanor, J.J</creator><creator>El Sahly, H.M</creator><creator>Gilbert, A</creator><creator>Meyer, A.L</creator><creator>Patriarca, P.A</creator><creator>Cox, M.M</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20091211</creationdate><title>Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old</title><author>Keitel, W.A ; Treanor, J.J ; El Sahly, H.M ; Gilbert, A ; Meyer, A.L ; Patriarca, P.A ; Cox, M.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-9ff764c264f52ff8ff3ef608832cc719d64dfdc486ee697fa2120cbbb808d6f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Antigens</topic><topic>Comparative immunogenicity</topic><topic>Eggs</topic><topic>Hemagglutinin Glycoproteins, Influenza Virus - immunology</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immune responses</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Influenza vaccines</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - adverse effects</topic><topic>Influenza Vaccines - immunology</topic><topic>Licenses</topic><topic>Multicenter Studies as Topic</topic><topic>Older people</topic><topic>Proteins</topic><topic>Recombinant hemagglutinin</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Recombinant Proteins - immunology</topic><topic>Seasons</topic><topic>Studies</topic><topic>Surveillance</topic><topic>Swine flu</topic><topic>Vaccines</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - adverse effects</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - adverse effects</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keitel, W.A</creatorcontrib><creatorcontrib>Treanor, J.J</creatorcontrib><creatorcontrib>El Sahly, H.M</creatorcontrib><creatorcontrib>Gilbert, A</creatorcontrib><creatorcontrib>Meyer, A.L</creatorcontrib><creatorcontrib>Patriarca, P.A</creatorcontrib><creatorcontrib>Cox, M.M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keitel, W.A</au><au>Treanor, J.J</au><au>El Sahly, H.M</au><au>Gilbert, A</au><au>Meyer, A.L</au><au>Patriarca, P.A</au><au>Cox, M.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2009-12-11</date><risdate>2009</risdate><volume>28</volume><issue>2</issue><spage>379</spage><epage>385</epage><pages>379-385</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 ≥65-year-old subjects in a randomized clinical trial. Virologic surveillance for influenza-like illness (ILI) was conducted during the 2006–2007 epidemic. Vaccines were well tolerated. Seroconversion rates vs. influenza A/H1N1 and H3N2 antigens were superior in the rHA group, but were inferior vs. influenza B; however, results for influenza B are confounded since the vaccine antigens were different. ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>19879222</pmid><doi>10.1016/j.vaccine.2009.10.037</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2009-12, Vol.28 (2), p.379-385 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733603122 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Aged Allergy and Immunology Antigens Comparative immunogenicity Eggs Hemagglutinin Glycoproteins, Influenza Virus - immunology Humans Illnesses Immune responses Immunization Immunogenicity Influenza vaccines Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza Vaccines - immunology Licenses Multicenter Studies as Topic Older people Proteins Recombinant hemagglutinin Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Recombinant Proteins - immunology Seasons Studies Surveillance Swine flu Vaccines Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - adverse effects Vaccines, Inactivated - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology |
| title | Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A00%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20immunogenicity%20of%20recombinant%20influenza%20hemagglutinin%20(rHA)%20and%20trivalent%20inactivated%20vaccine%20(TIV)%20among%20persons%20%E2%89%A565%20years%20old&rft.jtitle=Vaccine&rft.au=Keitel,%20W.A&rft.date=2009-12-11&rft.volume=28&rft.issue=2&rft.spage=379&rft.epage=385&rft.pages=379-385&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2009.10.037&rft_dat=%3Cproquest_cross%3E21166139%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1618927941&rft_id=info:pmid/19879222&rft_els_id=1_s2_0_S0264410X09015679&rfr_iscdi=true |